Quick Answer
Editas Medicine, Inc. reported R&D Expense of $89.95 million for fiscal year 2025.
Editas Medicine, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $89.95M | -54.9% |
| 2024 | $199.25M | +12.2% |
| 2023 | $177.65M | +1.5% |
| 2022 | $174.96M | +22.8% |
| 2021 | $142.51M | -9.8% |
| 2020 | $158.00M | +63.1% |
| 2019 | $96.90M | +6.9% |
| 2018 | $90.65M | +9.0% |
| 2017 | $83.16M | +45.9% |
| 2016 | $56.98M | +202.3% |
| 2015 | $18.85M | +271.5% |
| 2014 | $5.07M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.77M | -58.5% | +22.2% |
| June 30, 2025 | $16.18M | -70.2% | -39.2% |
| March 31, 2025 | $26.59M | -45.5% | -44.2% |
| September 30, 2024 | $47.64M | +17.6% | -12.1% |
| June 30, 2024 | $54.21M | +82.0% | +11.1% |
| March 31, 2024 | $48.79M | +29.1% | +20.4% |
| September 30, 2023 | $40.51M | -2.0% | +36.0% |
| June 30, 2023 | $29.78M | -31.8% | -21.2% |
- Editas Medicine, Inc. showed a decrease of -54.9% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Editas Medicine, Inc.’s r&d expense has grown by 1673.2% (from $5.07 million to $89.95 million).
- The most recent figure is from Editas Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: